Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

The acquisition was announced on Monday with James Walker, CEO of Agostini’s Pharmaceutical Group, presents at MDJL’s Carifta ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discu ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Emcure Pharmaceuticals posted a 35.4 per cent year-on-year (Y-o-Y) growth in its consolidated net profit at Rs 153.7 crore ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

But now, thanks to a combination of non-profit researchers and African public-health workers, there are signs of progress ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...